Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01886859

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +21 more
Locations: Stanford Cancer Institute Palo Alto Palo Alto, California, United States

University of Colorado Hospital Aurora, Colorado, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Completed

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

NCT01677858

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Arizona Oncology Associates Tucson, Arizona, United States

Comprehensive Blood and Cancer Center (CCBC) Bakersfield, California, United States

California Cancer Associates for Research and Excellence Encinitas, California, United States

Robert A. Moss, M.D., FACP, Inc. Fountain Valley, California, United States

View all 35 locations

View Trial Details

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

NCT02412878

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Research Site Scottsdale, Arizona, United States

Mayo Clinic Scottsdale, Arizona, United States

Research Site Bethesda, Maryland, United States

Center for Cancer and Blood Disorders Bethesda, Maryland, United States

View all 140 locations

View Trial Details

Completed

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

NCT01080391

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Mayo Clinic Scottsdale, Arizona, United States

Providence St. Joseph Medical Center Burbank, California, United States

St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare Santa Rosa, California, United States

Stanford University Stanford, California, United States

View all 127 locations

View Trial Details

Completed

Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists

NCT05036863

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Hämatologische Ambulanz - Tirol Kliniken Innsbruck, Tyrol, Austria

View Trial Details

Completed

Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals

NCT03581045

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: St. Jude Children's Research Hospital Memphis, Tennessee, United States

View Trial Details

Completed

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Novartis Investigative Site East Hanover, New Jersey, United States

View Trial Details

Completed

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

NCT05201911

Conditions: Amyloidosis, Amyloidosis, Hereditary, Transthyretin-Related, Amyloidosis; Systemic, +11 more
Locations: University of Tennessee Medical Center Knoxville, Tennessee, United States

View Trial Details

Completed

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

NCT02010931

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations: Research Site Brno, Czechia

Research Site Paris, France

Research Site Frankfurt am Main, Germany

Research Site Bologna, Italy

View Trial Details

Completed

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

NCT00493467

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions